ArticleScientific reports2026
ProSeg: multi-scale context fusion for high-precision prostate segmentation in MRI.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate MRI segmentation is critical for accurate diagnosis and treatment planning but remains challenging due to the complex interplay between the peripheral zone's thin, irregular boundaries and the central gland's homogeneous textures, compounded by variability across imaging protocols. To address these challenges, we propose ProSeg, a novel deep learning framework featuring a specialized ProSeg block that integrates dual complementary processes: (1) anisotropic convolutions for precise peripheral zone boundary delineation and (2) cross-slice attention mechanisms for robust central gland texture modeling. Extensive evaluations on the Promise12 and Promise158 datasets demonstrate ProSeg's state-of-the-art performance, achieving Dice scores of 84.31% (peripheral zone) and 57.92% (central gland) on Promise12, and 83.15% (peripheral zone) and 56.38% (central gland) on Promise158, significantly outperforming existing methods. ProSeg's consistent accuracy across diverse protocols highlights its clinical potential for reliable prostate zonal segmentation in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.